These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30920046)

  • 21. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
    Thibault V
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):145-147. PubMed ID: 29371018
    [No Abstract]   [Full Text] [Related]  

  • 22. Diabetes Mellitus is Associated With Higher Risk of Developing Decompensated Cirrhosis in Chronic Hepatitis C Patients.
    Saeed MJ; Olsen MA; Powderly WG; Presti RM
    J Clin Gastroenterol; 2017 Jan; 51(1):70-76. PubMed ID: 27306942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
    Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].
    Hamdane N; Baumert TF; Zeisel MB
    Med Sci (Paris); 2018 May; 34(5):391-394. PubMed ID: 29900836
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals.
    Liu J
    Hepatology; 2018 Jan; 67(1):453-454. PubMed ID: 29080221
    [No Abstract]   [Full Text] [Related]  

  • 27. Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?
    Wynter J; Stine JG; Shah NL
    Dig Liver Dis; 2016 Sep; 48(9):1101. PubMed ID: 27257048
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals - Authors' reply.
    Mücke MM; Mücke VT; Vermehren J
    Aliment Pharmacol Ther; 2017 Nov; 46(9):909-910. PubMed ID: 29023880
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter: low rates of HBV serology testing in patients with chronic hepatitis C receiving direct acting antivirals.
    Dimitroglou J; Zampetas D; Vasilieva L; Koullias E; Ketikoglou I; Alexopoulou A; Dourakis SP
    Aliment Pharmacol Ther; 2017 Nov; 46(9):908-909. PubMed ID: 29023878
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter: adoption of uniform nomenclature is crucial for estimating the true risk of HBV reactivation in patients treated with direct-acting antivirals for hepatitis C.
    Mücke MM; Mücke VT; Vermehren J
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1573-1574. PubMed ID: 29878415
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of effectively treated chronic hepatitis C infection in the development of type 2 diabetes mellitus.
    Purnak T
    Hepatology; 2009 Jun; 49(6):2131-2; author reply 2132. PubMed ID: 19437495
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial Commentary: Who is "Special" Now?
    Balagopal A; Thomas DL
    Clin Infect Dis; 2015 Sep; 61(5):826-8. PubMed ID: 25977267
    [No Abstract]   [Full Text] [Related]  

  • 35. Mortality associated with the treatment of HCV with direct-acting antivirals.
    Laurain A; Kramer L; Sultanik P; Vallet-Pichard A; Sogni P; Pol S
    Gut; 2018 Jan; 67(1):197-198. PubMed ID: 28341750
    [No Abstract]   [Full Text] [Related]  

  • 36. [Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent].
    Weiland O
    Lakartidningen; 2014 Nov; 111(51-52):2280-1. PubMed ID: 25423337
    [No Abstract]   [Full Text] [Related]  

  • 37. Benefits of Direct-Acting Antivirals for Hepatitis C.
    Lok AS; Chung RT; Vargas HE; Kim AY; Naggie S; Powderly WG
    Ann Intern Med; 2017 Dec; 167(11):812-813. PubMed ID: 29049502
    [No Abstract]   [Full Text] [Related]  

  • 38. Electrophysiological Adverse Effects of Direct-Acting Antivirals in Patients With Chronic Hepatitis C.
    Rossotti R; Garcia-Fraile Fraile LJ; Baiguera C; Puoti M
    J Clin Pharmacol; 2017 Jul; 57(7):931-932. PubMed ID: 28467638
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to "Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?".
    Vanni E; Bugianesi E; Saracco GM
    Dig Liver Dis; 2016 Sep; 48(9):1101-2. PubMed ID: 27443491
    [No Abstract]   [Full Text] [Related]  

  • 40. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
    Kawano A; Shigematsu H; Miki K; Ichiki Y; Morita C; Yanagita K; Takahashi K; Dohmen K; Nomura H; Ishibashi H; Shimoda S
    Intern Med; 2018 Jun; 57(11):1533-1542. PubMed ID: 29321441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.